WHO indicates preferred HIV treatment 01-Aug-2019 By Vassia Barba Citing evidence from two completed clinical trials, the WHO recommends dolutegravir as the preferred treatment for all patients with HIV.
update - WHO outlines biosimilarity requirements and inspection plan WHO plans biosimilar prequalification scheme to increase access to cancer meds 04-May-2017 By Gareth Macdonald The WHO has announced plans to extend its prequalification scheme to include cancer biosimilars and says it will pressure industry for fairer prices for all biologics.
